Catriona Yale Sells 10,000 Shares of Akero Therapeutics, Inc. (NASDAQ:AKRO) Stock

Akero Therapeutics, Inc. (NASDAQ:AKRO) insider Catriona Yale sold 10,000 shares of the firm’s stock in a transaction dated Monday, March 17th. The shares were sold at an average price of $44.76, for a total value of $447,600.00. Following the completion of the sale, the insider now owns 95,034 shares of the company’s stock, valued at approximately $4,253,721.84. This represents a 9.52 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website.

Catriona Yale also recently made the following trade(s):

• On Wednesday, March 12th, Catriona Yale sold 614 shares of Akero Therapeutics stock. The shares were sold at an average price of $44.88, for a total value of $27,556.32.
• On Tuesday, February 18th, Catriona Yale sold 10,000 shares of Akero Therapeutics stock. The stock was sold at an average price of $49.87, for a total value of $498,700.00.

Akero Therapeutics Price Performance

NASDAQ AKRO opened at $43.53 on Wednesday. The firm’s 50-day simple moving average is $42.78 and its two-hundred day simple moving average is $34.13. Akero Therapeutics, Inc. has a 52 week low of $17.86 and a 52 week high of $58.40. The company has a quick ratio of 17.25, a current ratio of 17.25 and a debt-to-equity ratio of 0.05. The company has a market cap of $3.47 billion, a PE ratio of -11.61 and a beta of -0.19.

Akero Therapeutics (NASDAQ:AKRO) last released its quarterly earnings data on Friday, February 28th. The company reported ($0.99) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.98) by ($0.01). Research analysts predict that Akero Therapeutics, Inc. will post -3.99 earnings per share for the current year.

Institutional Trading of Akero Therapeutics

Hedge funds and other institutional investors have recently made changes to their positions in the stock. GF Fund Management CO. LTD. bought a new position in Akero Therapeutics in the 4th quarter worth about $41,000. Sterling Capital Management LLC lifted its holdings in shares of Akero Therapeutics by 764.3% in the fourth quarter. Sterling Capital Management LLC now owns 1,789 shares of the company’s stock worth $50,000 after buying an additional 1,582 shares in the last quarter. Quarry LP bought a new position in shares of Akero Therapeutics in the fourth quarter valued at approximately $83,000. Summit Investment Advisors Inc. grew its stake in Akero Therapeutics by 6.8% during the fourth quarter. Summit Investment Advisors Inc. now owns 7,092 shares of the company’s stock valued at $197,000 after acquiring an additional 450 shares in the last quarter. Finally, Summit Financial Wealth Advisors LLC bought a new stake in Akero Therapeutics during the 3rd quarter worth approximately $205,000.

Analysts Set New Price Targets

AKRO has been the subject of a number of recent research reports. HC Wainwright boosted their price target on shares of Akero Therapeutics from $72.00 to $75.00 and gave the company a “buy” rating in a research note on Monday, March 3rd. Morgan Stanley reissued an “overweight” rating on shares of Akero Therapeutics in a research report on Sunday, March 2nd. Citigroup raised their price target on shares of Akero Therapeutics from $65.00 to $80.00 and gave the company a “buy” rating in a research report on Tuesday, January 28th. Bank of America raised Akero Therapeutics from a “neutral” rating to a “buy” rating and boosted their price objective for the stock from $35.00 to $63.00 in a report on Thursday, January 30th. Finally, UBS Group raised their target price on Akero Therapeutics from $42.00 to $109.00 and gave the company a “buy” rating in a report on Friday, January 31st. Nine analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company has an average rating of “Buy” and a consensus price target of $76.29.

About Akero Therapeutics

Akero Therapeutics, Inc, together with its subsidiary, engages in the development of treatments for patients with serious metabolic diseases in the United States. The company's lead product candidate is efruxifermin (EFX), which is in Phase 3 clinical trials that protects against cellular stress and regulates the metabolism of lipids, carbohydrates, and proteins throughout the body for the treatment of biopsy-confirmed metabolic dysfunction-associated steatohepatitis (MASH) patients.